Cargando…
Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
Glioblastoma multiforme (GBM) is the most aggressive and fatal disease of all brain tumor types. Most therapies rarely provide clinically meaningful outcomes in the treatment of GBM. Although antibody-drug conjugates (ADCs) are promising anticancer drugs, no ADCs have been clinically successful for...
Autores principales: | Anami, Yasuaki, Otani, Yoshihiro, Xiong, Wei, Ha, Summer Y.Y., Yamaguchi, Aiko, Rivera-Caraballo, Kimberly A., Zhang, Ningyan, An, Zhiqiang, Kaur, Balveen, Tsuchikama, Kyoji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195180/ https://www.ncbi.nlm.nih.gov/pubmed/35613589 http://dx.doi.org/10.1016/j.celrep.2022.110839 |
Ejemplares similares
-
Homogeneous antibody–angiopep 2 conjugates for effective brain targeting
por: Anami, Yasuaki, et al.
Publicado: (2022) -
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
por: Yamazaki, Chisato M., et al.
Publicado: (2021) -
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
por: Anami, Yasuaki, et al.
Publicado: (2018) -
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model
por: Zhao, Peng, et al.
Publicado: (2022) -
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)